Chinese Journal of Pharmacovigilance ›› 2014, Vol. 11 ›› Issue (7): 439-442.
Previous Articles Next Articles
ZHAO Huai-quan
Received:
2016-02-03
Revised:
2016-02-03
Online:
2014-07-08
Published:
2016-03-02
CLC Number:
ZHAO Huai-quan. Patient Safety Objective and Construction of Medicine Risk Management System in Medical Institutions[J]. Chinese Journal of Pharmacovigilance, 2014, 11(7): 439-442.
Add to citation manager EndNote|Ris|BibTeX
[1] WHO.关于患者安全的10个事实[EB/OL].(2007-05-08)[2014-01-20].http://www.who.int/features/factfiles/patient_safety/zh/. [2] WHO.启动全球患者安全挑战[EB/OL].(2005-10-13)[2014-01-20]. http://www.who.int/mediacentre/news/releases/2005/pr50/zh/. [3] 中国医院协会.关于发布和实施《2009年度患者安全目标》的通知[EB/OL].(2009-02-13)[2014-01-20].http://www.cha.org.cn/plus/list.php?tid=223. [4] WHO.世界卫生组织及伙伴呼吁加强研究以改善患者安全[EB/OL].(2007-09-24)[2014-01-20]. http://www.who.int/mediace-ntre/news/releases/2007/pr52/zh/index.html. [5] WHO. 患者安全解决方案[EB/OL].(2007-05-01)[2014-01-20].http://www.who.int/patientsafety/solutions/patientsafety/Patient-SolutionsCHINESE.pdf. 6] 沈云玉. 门诊处方调剂内差分析及防范措施探讨[J]. 中国药物警戒,2013,10(11):693-695. [7] 卫生部.药品不良反应报告和监测管理办法[EB/OL].(2011-05-04)[2014-01-20].http://www.moh.gov.cn/mohzcfgs/pgz/201105/51770.shtml. [8] 国家食品药品监督管理总局.发布2012年药品不良反应监测年度报告[EB/OL].(2013-03-14)[2014-01-20]. http://www.sda.gov.cn/WS01/CL0051/79058.html. [9] 张晓娟,杨敏. 药物整合在防范心血管内科患者用药差错中的作用[J].中国药学杂志,2013,48(3):234-236. [10] 刘萍,张卫同,徐子玲,等.门诊药房常见的发药差错原因与防范措施分析[J].中国药房,2013, 24(37):3547-3550. [11] 田旭,孙丽蕊,张红梅,等.品管圈活动在提高我院门诊处方合格率中的应用[J].中国药房,2013,24(25):2344-2346. [12] 中国药学会医院药学专业委员会.高危药品分级管理策略及推荐目录[EB/OL].(2012-03-31)[2014-01-20].http://www.cpahp.org.cn/ccyyf/news/201203/1435.htm. |
[1] | ZHAO Jie, GAO Minge, CHANG Hong, FAN Huixia. Pathogen Distribution, Drug Resistance and Drug Use in Neonates with Necrotizing Enterocolitis Complicated with Sepsis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 909-913. |
[2] | QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao. Research Progress in Integration Sites for Cellular and Gene Therapy Products [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727. |
[3] | LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan. Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785. |
[4] | ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789. |
[5] | LI Qiurong, FU Miaoqing, ZHOU Baishui, LI Cui, XIAO Xiaotong, YU Yuping, DENG Lu. Mining of Real-World ADR Signals Related to Cefradine for Injection in 268 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 790-793. |
[6] | LI Can, LIU Lehuan, CHEN Xia, QU Jianbo. Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569. |
[7] | YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao. A National Pharmacovigilance Management System in a New Era [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281. |
[8] | LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan. Methods for Assessment of MAH Compliance with GVP [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 282-285. |
[9] | ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi. Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 188-192. |
[10] | LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui. Developments and Prospects of Radiopharmaceuticals in China [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42. |
[11] | SONG Fuyu, CAO Yi. Establishment of Key Performance Indicators for Drug Inspection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1411-1414. |
[12] | ZHAO Peipei, WEN Baoshu. Regulation of cellular and gene therapies at home and abroad [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1019-1024. |
[13] | YANG Le, SHAN Lianlian, WANG Yali, YAN Shunhua, ZHOU Gang, CHEN Jia, WEI Feng. Quality standard for licorice of different sources [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1025-1028. |
[14] | SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng. Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899. |
[15] | WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru. Foreign methods for benefit-risk assessment of pharmaceutical products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||